Reduced-dose Chemotherapy Followed by Blinatumomab in Induction Therapy of Newly Diagnosed Non-elderly Ph-B-ALL

NCT05557110 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

35

Enrollment

OTHER

Sponsor class

Conditions

B Acute Lymphoblastic Leukemia

Interventions

DRUG: Blinatumomab

Sponsor

Chen Suning